- Home
- REI vs BCYC Comparison
REI vs BCYC Comparison
Compare REI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REI | BCYC |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.3M | 291.8M |
| IPO Year | 2013 | 2019 |
Fundamental Metrics
Financial Performance| Metric | REI | BCYC |
|---|---|---|
| Price | $1.40 | $4.00 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $13.90 |
| AVG Volume (30 Days) | ★ 3.4M | 309.6K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $307,178,072.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.83 | $3.75 |
| 52 Week High | $2.00 | $9.16 |
Technical Indicators
Market Signals| Indicator | REI | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 63.76 | 43.84 |
| Support Level | $1.23 | $3.94 |
| Resistance Level | $1.42 | $4.21 |
| Average True Range (ATR) | 0.06 | 0.14 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 93.18 | 41.94 |
Price Performance
Historical ComparisonAbout REI Ring Energy Inc.
Ring Energy Inc is an independent oil and natural gas exploration and production company based in the United States. It is engaged in oil and natural gas development, production, acquisition, and exploration activities, currently focused on the Permian Basin of Texas. The company's drilling operations target the oil and liquids-rich producing formations in the Northwest Shelf and the Central Basin Platform, in the Permian Basin in Texas.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.